Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Realty stocks lead among gainers
Wed, 18 Dec 01:30 pm

Indian markets continued to trade in the green during the post noon trading session. All the sectoral indices are trading in green with stocks from realty and capital goods space leading the gains.

BSE-Sensex is up by 265 points and NSE-Nifty is trading up by 85 points. While BSE Mid Cap index is trading up by 1.15%, BSE Small Cap index is trading down by 0.87%. The rupee is trading at 61.89 to the US dollar.

With inflation levels remaining high, the Reserve Bank of India (RBI)in its monetary policy has kept key rates unchanged. Thus repo rate and Cash Reserve Ratio were maintained at 7.75% and 4% respectively whereas the Marginal Standing Facility was kept at 8.75%. RBI's stance of keeping status quo also stems from the uncertainty surrounding the outlook for inflation with signs of likely fall in vegetable prices and weak state of the economy. The Wholesale Price Inflation for the month of November shot up to a 14-month high of 7.5% YoY on the back of high food prices. The RBI governor has said that that there are indications from the metros that the vegetable prices are expected to fall significantly both at the wholesale and retail level which has lent credence to keeping interest rates stable. At the same time, RBI has said that it will remain vigilant on inflation levels in the economy and also the possibility of tapering of quantitative easing by the US Fed that can disrupt external markets.

Most of the Indian pharma stocks are trading in green with Orchid chemicals and Biocon Ltd among the leading losers. According to a financial daily, Ranbaxy Laboratories received approval for Plendil generics for all the three strengths viz; 2.5mg, 5mg, and 10mg from USFDA (United States Food and Drug Administration). This drug is used to cure hypertension. There are already 6-7 players for this drug and has the market size of US$ 60 m. The size of the drug is quite small and thus Ranbaxy will not have any material benefit. However, with this approval coming in, it is expected that the company will also receive approval for its pending drugs in some time. Ranbaxy is currently trading down by 0.5%

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Realty stocks lead among gainers". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.